BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more
Market Cap & Net Worth: BioNxt Solutions Inc. (BNXTF)
BioNxt Solutions Inc. (OTCQB:BNXTF) has a market capitalization of $36.75 Million ($36.75 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #22968 globally and #8068 in its home market, demonstrating a -23.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioNxt Solutions Inc.'s stock price $0.30 by its total outstanding shares 122485519 (122.49 Million).
BioNxt Solutions Inc. Market Cap History: 2019 to 2025
BioNxt Solutions Inc.'s market capitalization history from 2019 to 2025. Data shows change from $91.86 Million to $36.75 Million (-14.16% CAGR).
BioNxt Solutions Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioNxt Solutions Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
802.95x
BioNxt Solutions Inc.'s market cap is 802.95 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $91.86 Million | $208.12K | -$7.67 Million | 441.40x | N/A |
| 2020 | $183.70 Million | $345.65K | -$16.89 Million | 531.47x | N/A |
| 2021 | $104.60 Million | $286.50K | -$20.64 Million | 365.11x | N/A |
| 2022 | $47.52 Million | $297.44K | -$12.38 Million | 159.78x | N/A |
| 2023 | $46.65 Million | $372.25K | -$7.72 Million | 125.33x | N/A |
| 2024 | $21.67 Million | $26.98K | -$5.31 Million | 802.95x | N/A |
Competitor Companies of BNXTF by Market Capitalization
Companies near BioNxt Solutions Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to BioNxt Solutions Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
BioNxt Solutions Inc. Historical Marketcap From 2019 to 2025
Between 2019 and today, BioNxt Solutions Inc.'s market cap moved from $91.86 Million to $ 36.75 Million, with a yearly change of -14.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $36.75 Million | +69.59% |
| 2024 | $21.67 Million | -53.56% |
| 2023 | $46.65 Million | -1.83% |
| 2022 | $47.52 Million | -54.57% |
| 2021 | $104.60 Million | -43.06% |
| 2020 | $183.70 Million | +99.97% |
| 2019 | $91.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BioNxt Solutions Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.75 Million USD |
| MoneyControl | $36.75 Million USD |
| MarketWatch | $36.75 Million USD |
| marketcap.company | $36.75 Million USD |
| Reuters | $36.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.